Praluent approved to reduce CV risk in EuropeThe European Commission has approved Sanofi and Regeneron’s Praluent for reducing cardiovascular risk in adults with established atherosclerotic Share XPraluent approved to reduce CV risk in Europehttps://pharmaphorum.com/news/praluent-approved-to-reduce-cv-risk-in-europe/
Praluent not worth the price, finds studySanofi and Regeneron’s Praluent may still not be cost effective compared to other cholesterol-lowering drugs despite a recent Share XPraluent not worth the price, finds studyhttps://pharmaphorum.com/news/praluent-not-worth-the-price-finds-study/
